Exel

Frank Karbe has served as Executive Vice President, Chief Financial Officer since July 2007. Previously, he served as Senior Vice President and Chief Financial Officer from February 2004 until July 2007. Mr. Karbe joined Exelixis from Goldman Sachs & Co., where he served most recently as vice president in the healthcare group. Prior to Goldman Sachs, Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. In addition to his broad experience in the areas of mergers & acquisitions and corporate finance he also brings a breadth of knowledge in the biotechnology and pharmaceutical industries. Mr. Karbe holds a Diplom Kaufmann from the WHU - Otto Beisheim Graduate School of Management, Koblenz, Germany (equivalent to a U.S. Masters of Business Administration).

Gisela M. Schwab, M.D., has served as Executive Vice President and Chief Medical Officer from January 2008. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. Since her arrival she has played a major role in the expansion of the number of later stage clinical trials and the growth and integration of the Clinical Development group within the entire R&D organization. Prior to joining Exelixis, Dr. Schwab served as senior vice president and chief medical officer at Abgenix, Inc., a human antibody- based drug development company that was acquired by Amgen, Inc. in April 2006. Prior to working at Abgenix, Dr. Schwab held various roles of increasing responsibility at Amgen Inc., most recently as therapeutic area leader for the clinical development of Amgen's hematology and oncology pipeline. Dr. Schwab received her Doctor of Medicine degree from the University of Heidelberg, trained at the National Cancer Institute and is board certified in internal medicine and hematology and oncology.

Frances K. Heller, JD, joined the company in September 2008 as Executive Vice President of Business Development. Ms, Heller has more than 15 years of pharmaceutical and biopharmaceutical industry experience. From 2003 too 2008, Ms. Heller was Head of Strategic Alliances at Novartis Institutes for Biomedical Research (NIBR), the global research organization for Novartis AG. In this position, she negotiated transactions around promising early-stage assets to accelerate NIBR’s drug discovery and development efforts. From 2001 to 2003, she served as Vice President of Corporate Development & Legal Affairs at Signature BioScience, Inc., an oncology drug discovery company, where she oversaw partnering and licensing activities. From 1998 to 2001, she had been Corporate and Intellectual Property Counsel for Celera Genomics, where she was head of the legal department and responsible for corporate and business transactions and gene discovery collaborations. Prior to 1998, Ms. Heller had various positions in business development, licensing, marketing and intellectual property management. Ms. Heller is a member of the California State Bar, is licensed by the US Patent and Trademark Office and received her JD degree from the Golden Gate University School of Law, her MA in biology from American University, and her BS in biology from Tulane University.

Ms. Rivera has served as Senior Vice President, Operations since July 2007. Previously, she served as Vice President, Human Resources and Communications from July 2004 through December 2006 and Exelixis’ Human Resources Director from January 2002 through June 2004. She joined Exelixis in 2002 from AT&T's Digital Subscriber Line (DSL) unit where she held the position of District Manager, Human Resources. Prior to joining AT&T, she was Director, Human Resources for NorthPoint Communications, and prior to that she held various positions with Deltanet, an information technology company. Ms. Rivera also spent twelve years in banking with Valley National Bank of Arizona and Bank One, Arizona. Ms. Rivera holds a Master of Human Resources & Organization Development from University of San Francisco. Ms. Rivera is a certified Senior Professional in Human Resources (SPHR) by the Human Resource Certification Institute and a Certified Compensation Professional (CCP) from World at Work (formerly known as the American Compensation Association).

D. Ry Wagner, PhD, Vice President of Research, Exelixis Plant Sciences joined Exelixis in December 2000. Dr. Wagner had previously served as Vice President of Research for Agritope, Inc, now Exelixis Plant Sciences. Prior to his appointment at Agritope, Dr. Wagner was on the faculty of the University of Oregon at the Institute of Molecular Biology, most recently serving as Associate Professor of Biology. He was a post-doctoral fellow with Drs. Jim Peacock and Liz Dennis from 1985 to 1988. He is the author of over 30 research publications related to the discovery and isolation of genes from yeast and flowering plants. Dr. Wagner received his BS degree in Botany and Plant Pathology from Michigan State University in 1978 and his PhD in Genetics from the University of Washington in 1985.

Stelios Papadopoulos, Ph.D. is a co-founder of Anadys and has served as a member of our board of directors since May 2000. His career in biotech spans more than two decades. In August 2006 he resigned as Vice Chairman of Cowen & Co., LLC where he had been an investment banker focused on the biotechnology and pharmaceutical sectors since 2000. Dr. Papadopoulos was an investment banker at PaineWebber Incorporated from 1987 to 2000, most recently serving as Chairman of Paine Webber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Prior to joining PaineWebber in 1987 he was a Vice President in the Equity Research Department of Drexel Burnham Lambert covering the biotechnology industry and a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. He is co-founder and Chairman of the Board of Exelixis, Inc., co-founder and member of the Board of Cellzome Inc., as well as a member of the Board of Directors of Biogen Idec and BG Medicine, Inc. In the not-for-profit sector, he is co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.

Jean-Francois Formela, M.D., is a Senior Partner in the life sciences sector for Atlas Venture, a venture capital firm, and has served as a member of our board of directors since June 1999. Prior to joining Atlas Venture in 1993, Dr. Formela was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough Corporation in the United States. During his tenure at Schering-Plough, he was responsible for the marketing of Intron A, Schering-Plough s alpha-interferon. In his last position at Schering-Plough, he directed the U.S. Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Dr. Formela practiced emergency medicine at Necker University hospital in Paris. Since joining Atlas Venture, he has been involved in the formation of companies such as ArQule, Inc., MorphoSys, Exelixis, Inc., deCODE genetics, Inc., Nuvelo, Inc., Cellzome AG, Archemix Corp. and Aureon Biosciences Corporation. Dr. Formela currently serves as a director of Achillion Pharmaceuticals, Inc., Arca Discovery, Inc. Cellzome Inc., Compound Therapeutics, NxStage Medical, Inc. and Resolvyx Pharmaceuticals, Inc. He holds an M.D. degree from the Paris University School of Medicine and an M.B.A. from Columbia University.

Dr. Morrissey has served as President of Research and Development since January of 2007. He served as Executive Vice President of Discovery from January, 2006 to December 2006. Previously he served as Senior Vice President of Discovery from January 2003 through December 2005 and Vice President of Discovery Research from February 2000 through December 2002. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research, where he was responsible for all aspects of drug discovery. During this time, Dr. Morrissey led the effort to expand and modernize the drug discovery capabilities at Berlex through the application of high throughput screening, combinatorial and medicinal chemistry, and structural biology. From 1986 to 1991, he served as a senior scientist and project team leader in medicinal chemistry at CIBA-Geigy Corporation, a pharmaceutical company. Over the past eighteen years, Dr. Morrissey has led discovery efforts that identified thirteen clinical candidates, including four have advanced to Phase II clinical trials for a variety of cardiovascular and inflammatory indications. He is the author of numerous scientific publications in medicinal chemistry and drug discovery, and an inventor on 52 issued US patents and 18 additional published US patent applications. Dr. Morrissey received his PhD in Chemistry from Harvard University and his BS Honors in Chemistry from the University Wisconsin.

Alan M. Garber, M.D., Ph.D., age 53, has been a director since January 2005. Dr. Garber has been the Henry J. Kaiser Jr. Professor and a Professor of Medicine at Stanford University since 1998. Dr. Garber is also a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. Dr. Garber is the Director of the Center for Primary Care and Outcomes Research at Stanford University School of Medicine, the Center for Health Policy at Stanford University and the Health Care Program of the National Bureau of Economic Research. He is a Senior Fellow at the Freeman Spogli Institute for International Studies at Stanford University and a staff physician at the VA Palo Alto Health Care System. Dr. Garber is a member of the Institute of Medicine, the American Society of Clinical Investigation, and the Association of American Physicians. Dr. Garber is on the editorial board of acclaimed scientific journals and has received numerous awards and honors. Dr. Garber holds an A.B. summa cum laude , an A.M. and a Ph.D., all in Economics, from Harvard University, and an M.D. from Stanford University.

Dr. Sawyers is Chairman of Memorial Sloan-Kettering Cancer Center's Human Oncology and Pathogenesis Program (HOPP) and the first incumbent of the Marie Josee and Henry R. Kravis Chair. HOPP capitalizes on recent advances in understanding cancer cell biology and the development of molecularly targeted drugs and other rationally based interventions. It brings together physician-scientists from various clinical and scientific disciplines to conduct cutting-edge translational research across many types of cancer. Dr. Sawyers' work examines how signaling pathway abnormalities in cancer cells can be exploited as targets for new cancer drugs. The promise of this approach is best exemplified by Dr. Sawyers' key role in the clinical development of imatinib (Gleevec ), which targets the molecular cause of chronic myeloid leukemia (CML) with minimal side effects. His group subsequently deciphered the molecular basis for resistance to imatinib. Based on this insight, he led the development of a second drug called dasatinib, which is effective in CML patients whose disease fails to respond to imatinib. He has extended this approach to other diseases, including prostate cancer and glioblastoma, through laboratory-based studies that suggest new treatment strategies now undergoing clinical testing. Dr. Sawyers came to Memorial Sloan-Kettering after nearly two decades at the University of California, Los Angeles (UCLA). He received his undergraduate degree from Princeton University and his medical degree from The Johns Hopkins University. He completed a residency in internal medicine at the University of California, San Francisco, Medical Center and a clinical fellowship in hematology/oncology at the UCLA School of Medicine. He is also a Howard Hughes Medical Institute Investigator. His awards include the Doris Duke Distinguished Clinical Scientist Award, the Richard and Hinda Rosenthal Foundation Award, and the David A. Karnofsky Award.

Dr. Frank McCormick, Ph.D., F.R.S., is Professor of Microbiology and Immunology and Director at the Comprehensive Cancer Center and Cancer Research Institute at the University of California, San Francisco. Dr. McCormick completed his B. Sc. in Biochemistry at the University of Birmingham, England, and then he went on to earn his Ph.D. also in Biochemistry at the University of Cambridge. Dr. McCormick held postdoctoral fellowships at State University of New York at Stony Brook and the Imperial Cancer Research Fund, London. During the period between 1981 and 1990 Dr. McCormick was Director of Molecular Biology at the Cetus Corporation. He then advanced to the position of Vice President of Research, a title he next would assume for the Chiron Corporation. In 1996, he became Founder and Chief Scientific Officer for Onyx Pharmaceuticals. Also in 1996 Dr. McCormick was awarded Fellowship in the Royal Society. Dr. McCormick has 224 publications to his credit.

Array

is the Chairman of the Medical Oncology Service and Director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron University Hospital in Barcelona, Spain and a Professor of Medicine at the Universidad Autonoma de Barcelona. He has made significant contributions to the clinical development of several approved targeted cancer therapies, including trastuzumab, cetuximab, gefitinib and erlotinib. Dr. Baselga also is actively engaged in research and development of new classes of cancer therapies, such as ras farnesyltransferase inhibitors, m-TOR inhibitors and a variety of antiangiogenic agents. In addition to his academic responsibilities, Dr. Baselga also is a member of the Editorial Boards for Cancer Cell, Clinical Cancer Research and Investigational New Drugs. He has published over 150 peer-reviewed articles, in addition to over 300 abstracts and book chapters. He holds leadership positions in a number of cancer research organizations, including Scientific Chairman of the Spanish Breast Cancer cooperative group (SOLTI), Member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research (LICR) and is the President-Elect of the European Society for Medical Oncology (ESMO). Dr. Baselga received his M.D. degree from the Universidad Autonoma of Barcelona in 1982. He performed internal medicine residencies at Vall d'Hebron University Hospital in Barcelona and at State University of New York. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, subsequently joining the institution's staff.

Lance Willsey, MD has served as a director since May 2000. Dr. Willsey was a founding partner of DCF Capital from July 1998 to April 2002. From July 1997 to July 1998, Dr. Willsey served on the Staff Department of Urologic Oncology at Dana Farber Cancer Institute at Harvard University School of Medicine. From July 1996 to July 1997, Dr. Willsey served on the Staff Department of Urology at Massachusetts General Hospital at Harvard University School of Medicine, where he was a urology resident from July 1992 to July 1996. Dr. Willsey is also a director of Exelixis, Inc. Dr. Willsey holds a BS in physiology from Michigan State University and an MS in biology and an MD from Wayne State University. Patrick J. Zenner has served as a director since March 2003. In January 2001, Mr. Zenner retired from Hoffmann-La Roche Inc., North America, the prescription drug unit of the Roche Group, a leading research-based health care enterprise, where he served as President and Chief Executive Officer since 1993, and was a member of the global Pharmaceutical Executive Committee. Mr. Zenner joined Hoffmann-La Roche Inc. as a sales representative in 1969 and subsequently held a series of marketing and business development posts that culminated in his being named Vice President and General Manager of Roche Laboratories in 1982. He later spent two and a half years with Roche Holding Ltd. as head of international pharmaceutical marketing, development and regulation. In 1988, Mr. Zenner was elected to Hoffmann-La Roche's Executive Committee and Board of Directors, and appointed Senior Vice President of the pharmaceutical division. Mr. Zenner also serves as a director of ArQule, Inc., Curagen Corporation, Dendrite International, Inc., First Horizon Pharmaceuticals Corporation, Genta Inc., Geron Corporation, Praecis Pharmaceuticals, Inc, West Pharmaceutical Services, Inc. and Xoma Ltd. Mr. Zenner holds a BS in business administration from Creighton University and an MBA from Fairleigh Dickinson University and is a Trustee of both universities.

has been a director since May 2001. Since 1973, Dr. Marchesi has been a Professor of Pathology and Cell Biology at Yale University and, since 1991, the Director of the Boyer Center for Molecular Medicine at Yale University. In 1982, Dr. Marchesi co-founded Molecular Diagnostics, Inc., a diagnostic development company. Dr. Marchesi was formerly Chair of Pathology at the Yale-New Haven Hospital. Dr. Marchesi holds an MD from Yale University and a PhD from Oxford University, and is a member of the National Academy of Sciences and the Institute of Medicine.